Indoco Remedies Limited (INDOCO.NS)
INR 230.81
(2.86%)
INR 230.81
(2.86%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.52 Billion INR | -30.02% |
| 2022 | 2.17 Billion INR | -14.69% |
| 2021 | 2.55 Billion INR | 51.86% |
| 2020 | 1.68 Billion INR | 171.59% |
| 2019 | 619.08 Million INR | 695.71% |
| 2018 | -103.92 Million INR | -116.12% |
| 2017 | 644.63 Million INR | -32.49% |
| 2016 | 954.93 Million INR | -16.04% |
| 2015 | 1.13 Billion INR | -4.81% |
| 2014 | 1.19 Billion INR | 31.98% |
| 2013 | 905.2 Million INR | 29.75% |
| 2012 | 697.66 Million INR | 5.01% |
| 2011 | 664.37 Million INR | 3.69% |
| 2010 | 640.73 Million INR | -10.09% |
| 2009 | 712.62 Million INR | 27.1% |
| 2008 | 560.68 Million INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 728.5 Million INR | 32.28% |
| 2005 | 550.72 Million INR | 23.09% |
| 2004 | 447.4 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 114.3 Million INR | -43.56% |
| 2024 Q1 | 202.5 Million INR | -10.56% |
| 2023 Q2 | 543.9 Million INR | 30.43% |
| 2023 Q4 | 226.4 Million INR | -44.65% |
| 2023 Q3 | 409 Million INR | -24.8% |
| 2023 FY | 1.52 Billion INR | -30.02% |
| 2023 Q1 | 417 Million INR | -12.32% |
| 2022 Q2 | 725.5 Million INR | 38.24% |
| 2022 Q1 | 524.8 Million INR | -19.4% |
| 2022 FY | 2.17 Billion INR | -14.69% |
| 2022 Q4 | 475.6 Million INR | 5.15% |
| 2022 Q3 | 452.3 Million INR | -37.66% |
| 2021 Q2 | 669.9 Million INR | 3.59% |
| 2021 Q1 | 646.7 Million INR | 52.22% |
| 2021 FY | 2.55 Billion INR | 51.86% |
| 2021 Q3 | 543.9 Million INR | -18.81% |
| 2021 Q4 | 651.09 Million INR | 19.71% |
| 2020 FY | 1.68 Billion INR | 171.59% |
| 2020 Q2 | 421.5 Million INR | 42.78% |
| 2020 Q1 | 295.2 Million INR | 168.64% |
| 2020 Q4 | 424.85 Million INR | -1.88% |
| 2020 Q3 | 433 Million INR | 2.73% |
| 2019 Q2 | 145.9 Million INR | 168.69% |
| 2019 FY | 619.08 Million INR | 695.71% |
| 2019 Q4 | 109.88 Million INR | -36.41% |
| 2019 Q3 | 172.8 Million INR | 18.44% |
| 2019 Q1 | 54.3 Million INR | 182.87% |
| 2018 FY | -103.92 Million INR | -116.12% |
| 2018 Q2 | -55.1 Million INR | -3.57% |
| 2018 Q1 | -53.2 Million INR | 0.0% |
| 2018 Q3 | 70 Million INR | 227.04% |
| 2018 Q4 | -65.52 Million INR | -193.61% |
| 2017 FY | 644.63 Million INR | -32.49% |
| 2016 FY | 954.93 Million INR | -16.04% |
| 2015 FY | 1.13 Billion INR | -4.81% |
| 2014 Q1 | 277.2 Million INR | 0.0% |
| 2014 FY | 1.19 Billion INR | 31.98% |
| 2013 FY | 905.2 Million INR | 29.75% |
| 2013 Q1 | 172.1 Million INR | -14.28% |
| 2012 Q3 | 135.2 Million INR | 0.0% |
| 2012 FY | 697.66 Million INR | 5.01% |
| 2012 Q4 | 200.77 Million INR | 48.51% |
| 2011 FY | 664.37 Million INR | 3.69% |
| 2010 FY | 640.73 Million INR | -10.09% |
| 2009 FY | 712.62 Million INR | 27.1% |
| 2008 FY | 560.68 Million INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | 728.5 Million INR | 32.28% |
| 2005 FY | 550.72 Million INR | 23.09% |
| 2004 FY | 447.4 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 73.526% |
| Hester Biosciences Limited | 364.77 Million INR | -317.907% |
| Aarti Drugs Limited | 7.14 Billion INR | 78.676% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 51.268% |
| Albert David Limited | 1.33 Billion INR | -14.234% |
| Alembic Limited | 767.77 Million INR | -98.549% |
| Alkem Laboratories Limited | 19.46 Billion INR | 92.167% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -541.418% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -7279.938% |
| Brooks Laboratories Limited | -72.25 Million INR | 2209.838% |
| Eris Lifesciences Limited | 5.18 Billion INR | 70.581% |
| FDC Limited | 3.03 Billion INR | 49.752% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 83.023% |
| Gufic Biosciences Limited | 2.89 Billion INR | 47.322% |
| Hikal Limited | 1.49 Billion INR | -2.021% |
| Ind-Swift Limited | 1.22 Billion INR | -24.343% |
| Innova Captab Limited | 2.53 Billion INR | 39.828% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 69.155% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -612.203% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 70.622% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | 20.035% |
| Lupin Limited | 27.75 Billion INR | 94.508% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -5451.752% |
| Medico Remedies Limited | 277.11 Million INR | -450.091% |
| Morepen Laboratories Limited | 4.17 Billion INR | 63.477% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 60.818% |
| Orchid Pharma Limited | 2.36 Billion INR | 35.436% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 45.284% |
| RPG Life Sciences Limited | 2.29 Billion INR | 33.499% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -632.708% |
| Sigachi Industries Limited | 1.47 Billion INR | -3.427% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 139.565% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 66.916% |
| Themis Medicare Limited | 1.3 Billion INR | -16.982% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -24119.892% |
| Wanbury Limited | 1.7 Billion INR | 10.708% |
| Windlas Biotech Limited | 1.29 Billion INR | -17.362% |
| ZIM Laboratories Limited | 1.09 Billion INR | -38.82% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 24.123% |
| Ipca Laboratories Limited | 29.59 Billion INR | 94.849% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.539% |
| Venus Remedies Limited | 534.65 Million INR | -185.121% |
| Sakar Healthcare Limited | 495.5 Million INR | -207.645% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 98.541% |
| Divi's Laboratories Limited | 18.31 Billion INR | 91.674% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 65.927% |
| Mankind Pharma Limited | 40.86 Billion INR | 96.27% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | 61.394% |
| Neuland Laboratories Limited | 5.31 Billion INR | 71.336% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 79.787% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 76.556% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 96.642% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -145.464% |
| Wockhardt Limited | 140 Million INR | -988.857% |
| Bal Pharma Limited | 214.56 Million INR | -610.447% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 97.749% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -23.834% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -176.365% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 78.902% |
| Shilpa Medicare Limited | 3.76 Billion INR | 59.474% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 92.253% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -53750.007% |
| Granules India Limited | 6.52 Billion INR | 76.649% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -511.592% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 93.983% |
| NATCO Pharma Limited | 25.96 Billion INR | 94.128% |
| Suven Life Sciences Limited | -1.22 Billion INR | 224.357% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 70.829% |
| Alpa Laboratories Limited | 61.51 Million INR | -2378.095% |
| Lasa Supergenerics Limited | -458 Million INR | 432.835% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 137.045% |